Cartesian Therapeutics Inc. (RNAC) - Total Liabilities
Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) has total liabilities worth $436.51 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Cartesian Therapeutics Inc. to track the company's year-over-year net asset growth rate.
Cartesian Therapeutics Inc. - Total Liabilities Trend (2014–2025)
This chart illustrates how Cartesian Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See RNAC FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Cartesian Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Cartesian Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Robot Consulting Co., Ltd. ADS
NASDAQ:LAWR
|
USA | $965.36 Million |
|
Value Added Technology Co. Ltd
KQ:043150
|
Korea | ₩170.42 Billion |
|
New World Resources Ltd
AU:NWC
|
Australia | AU$1.75 Million |
|
RADCOM Ltd
F:RAM
|
Germany | €30.87 Million |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
USA | $12.99 Million |
|
Terra Santa Propriedades Agrícolas S.A.
SA:LAND3
|
Brazil | R$200.80 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
USA | $146.00 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Cartesian Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RNAC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cartesian Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual total liabilities of Cartesian Therapeutics Inc. from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $422.65 Million | -4.34% |
| 2024-12-31 | $441.82 Million | -40.71% |
| 2023-12-31 | $745.23 Million | +934.21% |
| 2022-12-31 | $72.06 Million | -47.54% |
| 2021-12-31 | $137.36 Million | -25.12% |
| 2020-12-31 | $183.44 Million | +101.20% |
| 2019-12-31 | $91.17 Million | +82.71% |
| 2018-12-31 | $49.90 Million | +1.25% |
| 2017-12-31 | $49.29 Million | +43.51% |
| 2016-12-31 | $34.34 Million | -78.44% |
| 2015-12-31 | $159.32 Million | +44.86% |
| 2014-12-31 | $109.98 Million | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more